| HOME >> BIOLOGY >> TECHNOLOGY |
Operating expenses:
Research and development 12,660 13,449 39,331 54,780
General and administrative 4,625 6,364 15,720 20,458
Total operating expenses 17,285 19,813 55,051 75,238
Loss from operations (17,259) (19,701) (54,968) (74,523)
Interest income 819 2,022 2,907 4,744
Interest expense (1,218) (1,551) (3,995) (2,534)
Loss from valuation of warrant
liability (9,119) - (6,751) -
Net loss $(26,777) $(19,230) $(62,807) $(72,313)
Basic and diluted net loss per
share $(0.29) $(0.23) $(0.71) $(0.88)
Shares used in computation of basic
and diluted net loss per share 91,723 82,965 88,762 82,356
September 30, December 31,
2008 2007
Balance Sheet Data:
Cash and cash equivalents $61,839 $75,721
Short-term investments 35,654 27,115
Long-term investments 9,077 17,739
Total assets 145,144 161,662
Warrant liability 21,313 -
Convertible senior subordinated
notes 85,250 85,250
Total stockholders' equity 13,579 40,377
| SOURCE Dendreon Corporation Copyright©2008 PR Newswire. All rights reserved |